Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development announced today that ADX71441 dose dependently reduced PMP22 expression comparable to baclofen in a preclinical transgenic model of Charcot-Marie-Tooth 1A disease (CMT1A).
Help employers find you! Check out all the jobs and post your resume.
